Founded in 2002, Jafron Biomedical Co., Ltd. specializes in the research, development, production, and sales of biomaterials and high-tech medical devices. It is a publicly listed company on the A-share Growth Enterprise Market (stock code: 300529) with blood purification products as its core business. The company consistently ranks among the top medical device listed companies in China by market value. It has been awarded the "Golden Bull Most Valuable Investment Award" in 2017, 2018, 2019, and 2021, ranked among the "Top 50 Growth Enterprise Market Listed Companies" for four consecutive years, and received the titles of "Best Shareholder Return Listed Company" and "Competitive Enterprise" on the Growth Enterprise Market in the Financial Billboard Awards in 2019. Jafron was also listed among the Top 100 Private Healthcare Enterprises in the 2020 Hurun China rankings, with tax contributions exceeding 1.1 billion yuan over the past three years.

Jafron Group has received prestigious awards, including the "National Science and Technology Progress Second Prize," "Guangdong Province Science and Technology Progress First Prize," and the "China Technology Market Association Golden Bridge Award." It has been recognized as a "National Torch Program Key High-tech Enterprise," "National Manufacturing Single Champion Demonstration Enterprise," and "National Technology Innovation Demonstration Enterprise." The company has undertaken two "National Key New Product Projects," three "National Torch Program Projects," as well as national and provincial projects such as the National Industrial Revitalization and Technology Transformation Project, National Major Scientific and Technological Achievement Transformation Project, National 12th Five-Year Science and Technology Support Plan Project, National Key R&D Project, and Guangdong Strategic Emerging Industry Core Technology Breakthrough Project. Jafron has established research platforms including a National Enterprise Technology Center, Academician Workstation, Postdoctoral Research Workstation, Provincial Engineering Research Center, Provincial Key Enterprise Laboratory, Provincial Engineering Technology Research and Development Center, and Provincial Doctoral Workstation. Jafron was among the first in China and the second in Guangdong Province to pass the medical device GMP inspection. Its products have obtained CE certification and ISO international quality management system certification, and the company has been rated as a Guangdong Province Quality Credit Class A Medical Device Manufacturer for 12 consecutive years. In 2019, it was selected as a "Benchmark Enterprise in the Pharmaceutical Industry for the 70th Anniversary of New China."

Jafron Group's original and world-leading series of hemoperfusion device, along with technologies such as whole-blood perfusion, artificial liver, combined artificial kidney, and adsorption-based extracorporeal circulation, are used in over 6,000 large and medium-sized hospitals across more than 30 provinces and cities in China. The products are also exported to over 90 countries, including Germany, the UK, and Italy, for the treatment of critical conditions such as uremia, liver failure, poisoning, and lupus erythematosus, saving hundreds of thousands of patients annually with a market share exceeding 70%.

The blood purification research and production base (Jafron Science and Technology Park) invested and built by Jafron Group was completed and put into operation in 2015, continuously expanding its industrial scale. The company has successively invested in three production bases in Zhuhai City and established new production and research enterprises in Beijing-Tianjin, Guangdong-Shenzhen, and Hubei, forming an industrial layout covering South China, Central China, and North China.

In the future, Jafron Group aims to build a unique blood purification full-industry chain integrating equipment, consumables, pharmaceuticals, insurance, chronic disease management, and medical services. By pursuing group-oriented, branded, and diversified development, Jafron is laying a solid foundation to achieve its vision of becoming a "world-class high-tech medical technology enterprise group."